tbuckley/cabot-search huggingface dataset:
Part 9: Adult Stroke
Journal: Circulation (2005)

Each year in the United States about 700 000 people of all ages suffer a new or repeat stroke. Approximately 158 000 of these people will die, making stroke the third leading cause of death in the United States.1,2 Many advances have been made in stroke prevention, treatment, and rehabilitation.3,4 For example, fibrinolytic therapy can limit the extent of neurologic damage from stroke and improve outcome, but the time available for treatment is limited.5,6 Healthcare providers, hospitals, and communities must develop systems to increase the efficiency and effectiveness of stroke care.3 The “7 D’s of Stroke Care”—detection, dispatch, delivery, door (arrival and urgent triage in the emergency department [ED]), data, decision, and drug administration—highlight the major steps in diagnosis and treatment and the key points at which delays can occur.7,8

This chapter summarizes the management of acute stroke in the adult patient. It summarizes out-of-hospital care through the first hours of therapy. For additional information about the management of acute ischemic stroke, see the AHA/American Stroke Association (ASA) guidelines for the management of acute ischemic stroke.9,10

The goal of stroke care is to minimize brain injury and maximize patient recovery. The AHA and ASA developed a community-oriented “Stroke Chain of Survival” that links actions to be taken by patients, family members, and healthcare providers to maximize stroke recovery. These links are





The AHA ECC stroke guidelines focus on the initial out-of-hospital and ED assessment and management of the patient with acute stroke as depicted in the algorithm Goals for Management of Patients With Suspected Stroke (Figure). The time goals of the National Institute of Neurological Disorders …
Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).
Authors: Athanasios Anagnostopoulos, Steven P. Treon, Konstantinos Zervas, Andrew Branagan, Dimitra Gika, Athanasios Zomas, Marie Christine Kyrtsonis, Amalia Vassou, Nikolaos Anagnostopoulos, Gerasimos Pangalis, Meletios A. Dimopoulos
Journal: Blood (2005)
PUB110 Clinical Results of an EPID-Based In-vivo Dosimetry for Lung Cancer Radiation Therapy
Authors: Stefano Giancaterino, Andrea De Nicola, Nico Adorante, Monica Di Tommaso, Marianna Trignani, Marianna Nuzzo, Domenico Genovesi, Maria Daniela Falco
Journal: Journal of Thoracic Oncology (2017)
N1922S Mutation In the Factor VIII A3 Domain Produces a Rate-Limiting, Domain-Specific Folding Defect Leading to Hyposecretion of a Functional Protein
Authors: Ryan J. Summers, Shannon L. Meeks, John F. Healey, Harrison C. Brown, Ernest T Parker, Christopher Doering, Christine L. Kempton, John (Pete) S. Lollar
Journal: Blood (2010)
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results.
Authors: Andrzej J Jakubowiak, William Bensinger, David Siegel, Todd M. Zimmerman, Jan M. Van Tornout, Carol Zhao, Anil Singhal, Kenneth Anderson
Journal: Blood (2009)
Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes
Authors: Valeria Santini, Domenico Girelli, Alessandro Sanna, Nicola Martinelli, Lorena Duca, Natascia Campostrini, Agostino Cortelezzi, Michela Corbella, Alberto Bosi, Gianluigi Reda, Maria Domenica Cappellini
Journal: Blood (2010)
P1.02-039 Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients
Authors: Álvaro Taus, Laura Camacho, Ainhoa Hernández, Gabriel Piquer, Eva López, Alba Dalmases, David Casadevall, Lara Pijuan, Max Hardy, Raquel Longarón, Pedro Rocha, Arnau Zafra, Joan Albanell, Beatriz Bellosillo, Edurne Arriola
Journal: Journal of Thoracic Oncology (2017)
P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: Daniel Shao-Weng Tan, Dae Ho Lee, Ross Soo, Sebastian Michels, Fabrice Barlesi, Randeep Sangha, Fabienne Le Gac, Philippe Pultar, Sabine Glaser, Xiaoming Cui, Mikhail Akimov, Enriqueta Felip
Journal: Journal of Thoracic Oncology (2017)
P2.02-059 New Treatment Strategy in Inoperabl Locoregionally Advanced NSCLC: C Arm Cone Beam CT-GuıDed Selective Intraarterial Chemotherapy
Authors: Mustafa Ozdogan, Saim Yılmaz, Seyda Gunduz, Akın Yıldız, Necdet Öz, Ayşegul Kargı, Metin Cevener, Gökhan Asal, Deniz Arslan, Vildan Kaya
Journal: Journal of Thoracic Oncology (2017)
What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike!
Authors: Joao A. de Andrade, Tracy Luckhardt
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

but some centers must have used it substantially more often, considering that only half of the centers reported any NIV use on Days 1 and 2. Also, given that NIV use in patients with severe ARDS was as prevalent as in those with mild ARDS, and that more recent NIV guidelines have made no recommendation for its use in acute lung injury or pneumonia (10) or have suggested its use only for mild ARDS (11), it appears that some centers in the LUNG SAFE study were overzealous in their application of NIV to patients with ARDS.Even more disturbing is the finding of the propensity-matched analysis showing increased ICU mortality associated with NIV over invasive ventilation in patients with ARDS with Pa O 2 /FI O 2 less than 150.In the context of the previous studies showing high NIV failure rates in patients with hypoxemic respiratory failure, as well as the more recent study by Frat and colleagues ( 6) showing advantages of HFNO over NIV, this observation raises the question of whether NIV should be used at all in sicker patients with ARDS.However, it seems premature to make such a recommendation, especially with the recent RCT (12) showing that in patients treated with NIV for ARDS, intubation (18 vs. 62%) and mortality rates were much lower during use of the helmet interface as compared with a full face mask.This suggests that the technique of administering NIV is an important determinant of success.We have learned not to rely too much on single RCTs to guide ICU management, so further studies are urgently needed to sort out the relative merits of NIV delivered via a face mask, helmet, or HFNO versus prompt intubation in the therapy of ARDS.In the meantime, though, NIV should be used with great caution, if at all, in patients with ARDS with more severe oxygenation defects.
Abstract 18260: Familial Beals- Hecht Syndrome Associated With Bicuspid Aortic Valve and Right Ventricular Apical Diverticulum. An Unusual Combination of Congenital Defects Diagnosed in Adulthood by Multimodality Imaging
Authors: Valeria E Duarte, Rayan Yousefzai, Timothy Paterick, A. Jamil Tajik
Journal: Circulation (2015)

Introduction: Congenital contractural arachnodactyly (CCA) is an autosomal dominant disorder. CCA is phenotypically similar to Marfan syndrome, typically not affecting the aorta or eyes. Right ventricle (RV) diverticulum with bicuspid aortic valve (BAV) and CCA is not described. Case: 48 year-old caucasian female: cardiac apical aneurysm, scoliosis, BAV, and diagnosis of CCA. CCA affected her mother, brother, and daughter. PE: 5’ 7", 128 pounds, scoliosis, arachnodactyly, wing span of 69”, Ghent Nosology score 5. Cardiac exam: unremarkable. CT chest: contrast: a 2.7 x 2.2 cm arterially enhancing thin-walled lobular structure at the cardiac apex communicating with RV. Echo: RV apical pouch: 2.2 x 1.7 cm, narrow neck - mild systolic expansion. RV size, function and strain: normal. BAV with trace AR. Ascending aorta: 3.5 cm. LVEF 73%. Cardiac MRI: 2 x 2 x 2.5 cm diverticulum arising from the RV apex, 5 mm neck communicating with the aneurysm and RV. No delayed enhancement of the myocardium/ RV diverticulum. Gene testing: 16 genes associated with familial thoracic aortic aneurysm and dissection tested. Patient: heterozygous for a novel D1532N variant in the FBN2 gene. This variant is not reported as a mutation or benign polymorphism. Discussion: CCA associated with BAV and RV diverticulum is not described. CCA is genetically linked to FBN2. Congenital ventricular diverticulum is a rare finding, very infrequently affecting the RV. Multimodality imaging and gene testing may lead to better identification of this malformation and its association with genetic diseases. There is no standardized treatment of RV diverticulum. This asymptomatic patient received conservative management.
Identification of HLA Allele Mismatch Combinations and Amino Acid Substitution Positions Associated with GVL Effect after Unrelated HSCT: Analysis from the Japan Marrow Donor Program.
Authors: Takakazu Kawase, Keitaro Matsuo, Koichi Kashiwase, Hidetoshi Inoko, Hiroh Saji, Shunichi Kato, Takehiko Sasazuki, Yoshihisa Kodera, Yasuo Morishima
Journal: Blood (2007)
<i>Let-7a</i> microRNA levels in <i>KRAS</i>-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR.
Authors: E. Canestrari, A. Ruzzo, B. Vincenzi, N. Galluccio, G. Perrone, F. Andreoni, P. Lorenzini, E. Rulli, S. d'Emidio, V. Catalano, F. Loupakis, R. Bisonni, I. Floriani, M. De Nictolis, D. Santini, L. Salvatore, G. Tonini, A. Falcone, M. Magnani, F. Graziano
Journal: Journal of Clinical Oncology (2011)

3635 Background: KRASis down-regulated by Let-7microRNA isoforms and this effect may be clinically relevant to patients harboring KRASmutations. We quantified the Let-7a isoform in KRAS-mutated colorectal carcinomas of patients who received salvage irinotecan/cetuximab. The Let-7a levels were characterized and studied for association with survival outcomes. Methods: The study population was retrospectively identified among metastatic colorectal cancer (mCRC) patients who underwent third-line cetuximab/irinotecan before 2008. At that time epidermal growth factor receptor (EGFR) expression only was required for adopting the anti-EGFR therapy. In 59 eligible patients harboring KRAS mutations, tumoral Let-7a levels were analyzed for association with overall survival (OS) and progression-free survival (PFS). An exploratory sub-group analysis was performed to detect the single nucleotide polymorphism (SNP) rs61764370 G/A (LCS6) in the region that experimentally impairs the Let-7 binding to the KRASmRNA. Results: Among clinico-pathologic features, high Let-7a levels were associated with grade 2-3 skin toxicity (p=0.002). Differences in Let-7alevels were not found between paired tumor and non-tumor samples in 39 cases (66%) with availability of both tissues. Increased Let-7a levels were significantly associated with improved survival (multivariate Hazard Ratio=0.88; 95%CI=0.79-0.98; p=0.02). In the exploratory analysis the variant G allele of the LCS6occurred in 14 patients and among the 45 A/A LCS6 homozygous patients, there was a significantly favorable association between high Let-7a levels and both OS and PFS. Conclusions: Replication of these data is warranted. In patients with KRAS mutation, Let-7analysis may serve for identifying subgroups who may still gain some benefit from EGFR inhibition and it may open new perspectives for alternative treatment strategies.
OA01.03 Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Stage I NSCLC Patients: A Competing Risk Analysis
Authors: Takashi Eguchi, Sarina Bains, Kay See Tan, Manjit Bains, Robert Downey, James Huang, James Isbell, Bernard Park, Valerie Rusch, David Jones, Prasad Adusumilli
Journal: Journal of Thoracic Oncology (2017)
Dynamic near-infrared spectroscopy assessment as an important tool to explore pulmonary arterial hypertension pathophysiology
Authors: Stavros Dimopoulos, Giorgos Tzanis, Andreas Karabinis, Serafim Nanas
Journal: European Respiratory Journal (2017)

With great interest we read the recent article by Panagiotou et al . [1] in which the authors investigated the correlation between tissue oxygen measurements ( S tO2) at rest and during constant-workload exercise with the analogous measurements of mixed venous oxygen saturation at the level of pulmonary artery ( S vO2) and inferior vena cava in patients with pulmonary arterial hypertension (PAH). In this study, the authors used near-infrared spectroscopy (NIRS) to assess the vastus lateralis muscle tissue oxygenation during exercise. Near-infrared spectroscopy: a useful methodology for pulmonary arterial hypertension <http://ow.ly/7wwQ3065Cpb>
P273 Baseline characteristics of patients with idiopathic pulmonary fibrosis aged over 80 years old
Authors: GA Margaritopoulos, A Proklou, D Badenes Bonet, M Kokosi, TM Maher, EA Renzoni, AU Wells, F Chua
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Idiopathic Pulmonary Fibrosis (IPF) is strongly associated with advanced age. Our aim is to identify if the baseline characteristics of patients aged &gt;80 who are excluded from pharmaceutical trials differ compared to patients aged &lt;80 years. <h3>Methods</h3> Consecutively diagnosed IPF patients ≥80 (n = 61) and &lt;80 (n = 320) presenting to the ILD Unit of the Royal Brompton Hospital from 1/1/2010 to 31/12/2013 were included in this analysis. Data regarding age, smoking status, pulmonary function tests including (FEV<sub>1</sub>, FVC, DLco and Kco) were extracted from medical records. All cases were discussed by an ILD multi-disciplinary panel for the purpose of assigning a consensus diagnosis. <h3>Results</h3> The baseline characteristics of both study groups are summarised in Table 1. Patients were also grouped by smoking status; the smoking history of 10 patients in the ≥80 and 3 patients in the &lt;80 groups was unavailable. We divided both groups to smokers and non-smokers. FEV<sub>1</sub> and FVC did not differ between non-smokers from both study groups whereas were both significantly lower in the smokers aged &lt;80 years than in smokers aged &gt;80 years (74,44 ± 18,24 versus 86,34 ± 12,67 p = 0.0005 for FEV<sub>1</sub> and 72,96 ± 20,77 versus 88,34 ± 13,68 p = 0.0001 for FVC). DLco and Kco did not differ between smokers and non-smokers. <h3>Conclusion</h3> Patients with IPF aged ≥80 years present with higher spirometric values than those &lt; 80 in particular when a history of smoking is taken into consideration. Mean FVC did not differ between the non-smoking cohorts in each age-separated group while baseline DLco and Kco were not different between the two study groups regardless of smoking status. The higher FVC in smokers with IPF aged &gt;80 compared to younger smokers could be due to the concomitant presence of radiologically evident emphysema. This finding has clinical implications with respect to eligibility for NICE-approved anti-fibrotic treatment. Analysis of the extent of emphysema in these patients and further studies of a higher number of patients is underway.
SON Regulates GATA-2 Through Transcriptional Control of the Mir-23a∼27a∼24-2 Cluster
Authors: Eun-Young Ahn, Tsunehito Higashi, Ming Yan, Shinobu Matsuura, Miao-Chia Lo, Wei-Jong Shia, Russell Dekelver, Dong-Er Zhang
Journal: Blood (2012)
90Y-Ibritumomab Treatment for Relapsed and/or Refractory B Cell Type Non-Hodgkin’s Lymphoma. Multiinstitutional Argentinian Study.
Authors: Roberto Cacchione, Juan Dupont, Jorge Milone, Javier Bordone, Guy Garay, Maria Ardaiz, Miguel Castro-Rios, Virginia Prates, Alfredo Basso, Marcelo Iabstrebner, Graciela Avila, Alicia Diaz, Daniel Argentieri, Silvia Rudoy, Alicia Trouboul, Luis Palmer, Gonzalo Pombo, Silvina Rappaciotti, Pedro Negri, Diana Lafalse, Leandro Riera, Miguel de Tezanos-Pinto, Dardo Riveros, Mario Brown Arnold, Antonio Carrasco, Fernando Bezares
Journal: Blood (2007)
Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes Myelodysplastic Syndrome From Normal Bone Marrow.
Authors: Head R. Head, Sara A. McClintock-Treep, Leanne flye-Blakemore, Claudio Mosse, Madan Jagasia, Andrew Shinar, William D Dupont, Greg Stelzer, Robert Briggs, Keith E Shults
Journal: Blood (2009)
Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia
Authors: Chris L. Pashos, Christopher R Flowers, Mark Weiss, Nicole Lamanna, Charles M Farber, Thomas J. Kipps, Susan Lerner, Neil Kay, Jeff Porte Sharman, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S Swern, Zeba M. Kahn, Thomas K. Street, Kristen A Sullivan, Gale Harding, Michael J Keating
Journal: Blood (2011)
P2.03b-087 PD-L1 Expression in Adenosquamous Lung Carcinoma and the Comparison with the Other Common Variants of Non-Small Cell Lung Cancer
Authors: Xiaohua Shi, Shafei Wu, Jian Sun, Yuanyuan Liu, Xuan Zeng, Zhiyong Liang
Journal: Journal of Thoracic Oncology (2017)
P2.03a-064 Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC
Authors: Lauren Mac Donagh, Steven Gray, Stephen Finn, Sinead Cuffe, Michael Gallagher, Kenneth O’Byrne, Martin Barr
Journal: Journal of Thoracic Oncology (2017)
P1.03-035 Does Screening with Low-Dose Computed Tomography (LDCT) of Asbestos Exposed Subjects Reduce Mortality for Lung Cancer (LC)?
Authors: Gianpiero Fasola, Ornella Belvedere, Fabio Barbone, Alessandro Follador, Fabiano Barbiero, Simona Rizzato, Ciro Rossetto, Elisa De Carlo, Paolo Cassetti, Stefano Meduri, Francesco Grossi
Journal: Journal of Thoracic Oncology (2017)
Flawed invisible trial underpins US morning sickness drug, researchers say
Authors: Owen Dyer
Journal: BMJ (2017)

A 1975 trial that led to the approval of the US’s only approved morning sickness drug—long buried in the Food and Drug Administration archives but newly published—is marred by “questionable data integrity” and should not be relied on “because of the high risk of bias,” say researchers who obtained the original trial from the FDA under a freedom of information request and published it in the journal PLoS One .1

The 40 year old research has been cited frequently by the FDA, Health Canada, and the drug’s manufacturer, Duchesnay, as the principal evidence for the safety and efficacy of the vitamin B6/doxylamine combination, formerly known as Bendectin …
MA10.03 Investigating the Potential Utility of the Alternative 9th Edition IASLC Nodal Staging Classification in NSCLC
Authors: Timothy Edwards, Haval Balata, Charlene Tennyson, Philip Foden, Anshuman Chaturvedi, Philip Crosbie, Richard Booton, Matthew Evison
Journal: Journal of Thoracic Oncology (2017)
Allogeneic Transplantation with Identical MHC: Clinic-Pronostic Value of Discrepances of Microsatellite DNA Regions between Recipient and Donor.
Authors: Miguel Alcoceba, María Díez-Campelo, Patricia Martín-Jiménez, María E. Sarasquete, Adriana Armellini, Lorena Blázquez, Carina Fernández, Carmen Chillón, Ana Balanzategui, M. V. Mateos, Ramón García-Sanz, Dolores Caballero, Marcos González, J.F. San Miguel
Journal: Blood (2004)
Cardiac tumors and gastroendoscopy: endoscopic resection of left ventricular tumors
Authors: Jun Arimoto, Takuma Higurashi, Shingo Kato, Shungo Goto, Satoru Suzuki, Atsushi Nakajima, Kazuhiro Atsukawa
Journal: Endoscopy (2017)

Endoscopic techniques have expanded in recent years and now have the potential to be useful not only in digestive diseases but also in diseases usually seen by other departments. Cardiac tumors require surgical resection to prevent tumor-mediated embolism [1]; however, a left ventriculotomy significantly decreases the ejection fraction [2].
Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients
Authors: Shahrukh K Hashmi, Daniel Wojenski, Gabriel Bartoo, Julianna A. Merten, Ross Dierkhising, Rokea Elazhary, John W Wilson, Robert Wolf, Mrinal M. Patnaik, William Hogan, Mark R. Litzow
Journal: Blood (2013)
Abstract A18: Development of a novel peptide therapeutic that targets ovarian cancer via the tumor microenvironment
Authors: Suming Wang, Anna Blois, Tina EI Rayes, Joyce F. Liu, Michelle S. Hirsch, Karsten Gravdal, Diane R. Bielenberg, Lars A. Akslen, Ronny Drapkin, Vivek Mittal, Randolph S. Watnick
Journal: Cancer Research (2016)

Abstract Ovarian cancer is the most lethal gynecologic malignancy and the fourth leading cause of cancer deaths in women. Pathologically, ovarian cancer is categorized into multiple subtypes, with epithelial ovarian cancer (EOC) representing 90% of cases. Despite our increased understanding of the biology governing the progression of EOC the survival rate for patients with stage IV EOC is only 17%. The vast majority of ovarian cancer-related deaths are caused by metastatic dissemination of cells from the primary tumor resulting in subsequent organ failure. Tragically, there are no clinically approved drugs that have shown significant efficacy at treating advanced, metastatic, ovarian cancer. As such, there is a dire need for efficacious therapies that can specifically treat advanced, metastatic ovarian cancer. We were the first to identify prosaposin (psap) as a potent inhibitor of tumor metastasis via stimulation of the anti-tumorigenic protein thrombospondin-1 (Tsp-1) in bone marrow-derived cells that are recruited to metastatic sites. We report here that virtually 100% of human serous ovarian tumors tested express CD36, the receptor that mediates the pro-apoptotic activity of Tsp-1. Accordingly, we developed a novel cyclic peptide with drug-like properties derived from the active sequence in psap. Strikingly, this cyclic psap peptide was able to significantly regress metastatic tumors in a patient-derived tumor xenograft (PDX) model of metastatic ovarian cancer. Thus, our findings suggest that development of a therapeutic agent based on this psap peptide would have significant efficacy in treating patients with metastatic ovarian cancer. Citation Format: Suming Wang, Anna Blois, Tina EI Rayes, Joyce F. Liu, Michelle S. Hirsch, Karsten Gravdal, Diane R. Bielenberg, Lars A. Akslen, Ronny Drapkin, Vivek Mittal, Randolph S. Watnick. Development of a novel peptide therapeutic that targets ovarian cancer via the tumor microenvironment. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr A18.
Clinical Characteristics in Neonates with Alloimmune Neutropenia: Significance of the Detection of Antineutrophil Antibodies
Authors: Yoko Mizoguchi, Kazuhiro Nakamura, Shuhei Karakawa, Takashi Sato, Rie Onodera, Emi Kurita, Asako Hiraoka, Kikuyo Taniguchi, Masao Kobayashi
Journal: Blood (2008)
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.
Authors: Partow Kebriaei, Timothy Madden, Reza Kazerooni, Elizabeth Shpall, Xuemei Wang, Peter Thall, Chitra Hosing, Muzaffar Qazilbash, Uday Popat, Celina Ledesma, Issa Khouri, Richard Champlin, Roy Jones, Borje S. Andersson
Journal: Blood (2009)
P1.08-034 Prognostic Impact of EGFR Mutation in Patients with Surgically Resected Lung Adenocarcinoma; Analysis about Subtypes of EGFR Mutations
Authors: Yohei Kawaguchi, Tetsuya Okano, Ken Taro Imai, Sachio Maehara, Maeda Junichi, Koichi Yoshida, Masaru Hagiwara, Masatoshi Kakihana, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda
Journal: Journal of Thoracic Oncology (2017)